Pramipexole (Sifrol) for early Parkinson’s disease Pramipexole (Sifrol) for early Parkinson’s disease

PBS listing | Reason for PBS listing | Place in therapy | Safety issues | Dosing issues
Information for patients | References

PBS listing

Restricted benefit

Parkinson's disease

Previously, the use of pramipexole was restricted to adjunctive therapy in people being treated with levodopa–decarboxylase inhibitor combinations. This listing allows pramipexole to be used as monotherapy in early stages of Parkinson's disease.

The listing also notes that:

• episodes of sudden-onset of sleep without warning, during activity, have been reported
• care should be taken when using dopamine agonists in older people with significant cognitive impairment.

Reason for PBS listing

The Pharmaceutical Benefits Advisory Committee (PBAC) recommended pramipexole for listing on a cost-minimisation basis — that is, similar efficacy and cost — compared with cabergoline for the treatment of Parkinson's disease.¹ This decision was based on an indirect comparison in which a randomised trial of pramipexole and a randomised trial of cabergoline were compared using levodopa as the common comparator.¹

Place in therapy

Pramipexole is a non-ergot dopamine agonist used for symptomatic treatment of Parkinson's disease and restless legs syndrome.

Selection of either a dopamine agonist (including pramipexole) or levodopa as treatment for early Parkinson's disease must be individualised for each person as it is not possible to identify a universal first-choice drug therapy.^2,3

Using pramipexole instead of levodopa in early Parkinson's disease delays the development of motor complications (wearing off, dyskinesias or on–off fluctuations).⁴ However, pramipexole is less effective than levodopa at treating the symptoms of Parkinson's disease and is associated with increased rates of somnolence, hallucinations and oedema.^4,5

When choosing initial therapy, consider levodopa for people whose major concern is control of existing motor symptoms and pramipexole for those more concerned about the development of motor complications because of longer levodopa use (e.g. younger people). Other factors to consider include:

• age — pramipexole may cause more adverse effects, such as hallucinations and confusion, in older people (over 65).^3,6,7
• cognitive impairment — pramipexole may cause more adverse effects, such as hallucinations and confusion, in people with cognitive impairment.^3,6,7
• the impact of somnolence on daily activities, as pramipexole causes more somnolence than levodopa.⁴

No trials have directly compared pramipexole with other dopamine agonists as monotherapy in early Parkinson's disease.

For further information on pramipexole in restless legs syndrome read the NPS RADAR review: Pramipexole (Sifrol) for severe primary restless legs syndrome.

Pramipexole delays motor complications but is less effective than levodopa at controlling Parkinson's symptoms

Randomised trials have compared pramipexole with placebo and levodopa in early Parkinson's disease. Against placebo, pramipexole produced modest, but statistically significant, mean improvements in motor scores and activities of daily living scores on the Unified Parkinson's Disease Rating Scale (UPDRS) in people with early disease.^8-10

A single trial (n = 301) compared the efficacy of pramipexole and levodopa in people with early disease.⁴ After 10 weeks of monotherapy, people in both groups could be given additional open-label levodopa to treat ongoing or emerging disability.⁴

After 2 years, motor complications (defined as the first instance of wearing off, dyskinesias or on–off fluctuations) were significantly less common in people treated with pramipexole than levodopa (28% vs 51%: hazard ratio [HR] 0.45, 95% confidence interval [CI] 0.30 to 0.66). However, people treated with levodopa experienced modest but significantly better symptomatic control over the 2 years of the trial.

More than half of the people using pramipexole required supplemental levodopa within 2 years, compared with 39% of those in the levodopa group (HR 1.54, 95% CI 1.09 to 2.17).

Within 4 years, significantly more people discontinued pramipexole than levodopa (44% vs 33%).⁵ After 4 years, freezing was more common in the pramipexole group than the levodopa group (37% vs 25%: HR 1.70, 95% CI 1.11 to 2.59).⁵ However, quality-of-life scores were similar in both groups.

No head-to-head trials of pramipexole and the other dopamine agonists in early Parkinson's disease

There are no head-to-head comparisons of pramipexole with any of the other dopamine agonists in early Parkinson's disease. An indirect comparison was presented in the PBAC submission, comparing a trial of pramipexole against a trial of cabergoline, using levodopa as the common comparator.

Suggest non-drug measures for everyone with Parkinson's disease

Physiotherapy, occupational therapy, and speech and language therapy are recommended for people with Parkinson's disease.²

A general therapeutic exercise program for individuals or groups includes exercises for the trunk and upper limbs, speech and breathing exercises, gait training, balance training, transfer training and relaxation.¹¹

Safety issues

Common adverse effects among people with early Parkinson's disease treated with pramipexole include nausea, somnolence, constipation, hallucinations, confusion, dizziness and oedema.¹² Sleep attacks and compulsive behaviour have been reported with pramipexole and other dopamine agonists.^12,13

The ergot-derived dopamine agonists cabergoline and pergolide increase the risk of valvular heart disease, but this has not been shown with pramipexole.^14,15 Whether non-ergot dopamine agonists, such as pramipexole, can cause such events is unknown.¹²

Report suspected adverse reactions to the Therapeutic Goods Administration (TGA) online or by using the 'Blue Card' distributed 3 times a year with Australian Prescriber. For information about reporting adverse reactions, see the TGA website.

More adverse effects with pramipexole than levodopa

Pramipexole causes more somnolence, oedema and hallucinations in people with early Parkinson's disease than levodopa (Table 1).⁴

Table 1: Comparison of the adverse effects of
pramipexole and levodopa*⁴

*All differences are statistically significant

†Includes peripheral, generalised, localised, facial, tongue or periorbital oedema or lymphodema

A retrospective analysis of data collected during the trial suggests the risk of developing oedema while using pramipexole appears to be greater in people with a history of cardiac disease. Hallucinations were associated with older age (≥ 65 years) and lower Mini-Mental State Examination scores.⁷

Pramipexole may cause somnolence and sleep attacks

Somnolence was a common drug-related adverse effect in trials of pramipexole.^4,5,9,10,12

Sudden onset of sleep during daily activities — in some cases without awareness or warning signs ('sleep attack') — has been reported in people with Parkinson's disease receiving pramipexole.¹³ Sleep attacks have been reported with all dopamine agonists and levodopa; it is not yet clear whether they are caused by the disease itself or if they are more frequent with some dopamine agonists.^2,6

Advise patients not to drive, use tools or operate machinery until the effects of pramipexole are known.

During the first 2 years of the trial comparing levodopa and pramipexole, 3 people reported falling asleep while driving; 2 were using pramipexole and 1 was using levodopa. Another 2 people using pramipexole reported sudden drowsiness unrelated to driving.⁴

People who have a sleep attack should refrain from driving and other dangerous activities until they receive medical advice (see Information for patients). Consider dose reduction or discontinue pramipexole in these cases.¹²

Dopamine agonists may cause compulsive behaviours

Inform patients and carers that there is a small risk of compulsive behaviours (e.g. pathological gambling, hypersexuality) but that the consequences can be serious, and to seek medical advice promptly if there are early signs of a developing problem.¹²

Dosing issues

For Parkinson's disease, pramipexole is taken 3 times daily in equally divided doses. Start with 125 micrograms taken 3 times per day (total daily dose 375 micrograms). Titrate the dose as required every 5–7 days to a maximum of 4.5 mg daily (Table 2).¹²

Table 2: Initial dose titration for Parkinson's disease*

*Early or advanced Parkinson's disease. Reduce the dose of levodopa when introducing pramipexole as adjunctive therapy in advanced disease.¹² A smaller dose is used to treat restless legs syndrome (see the Product Information).

Initial daily doses should be reduced if creatinine clearance is < 50 mL/min.¹²

Centrally active dopamine antagonists (i.e. antipsychotics or metoclopramide) diminish the effect of pramipexole. These drugs should not be used with pramipexole.¹²

Cimetidine, and possibly amantadine, may reduce renal excretion of pramipexole.^6,16

Information for patients

Advise patients:

• that pramipexole may cause sudden attacks of sleep in some people
• if they have a sleep attack at any time to refrain from driving and contact a doctor
• not to drive or perform dangerous tasks requiring constant attention until accustomed to the side effects
• that pramipexole may make them more susceptible to compulsive behaviours (e.g. compulsive gambling)
• that nausea, oedema and drowsiness are common side effects and that they may experience hallucinations
• that sedatives or alcohol may worsen any drowsiness.

Discuss the Sifrol (pramipexole) consumer medicine information (CMI) leaflet with the patient.

State and Territory Parkinson's organisations offer information and support for people with Parkinson's disease and their carers. Contact details for each can be found though Parkinson's Australia (www.parkinsons.org.au).

Medicine Update

An NPS Medicine Update leaflet on pramipexole is available for consumers. Medicine Update helps consumers to ask the right questions about new medicines, and helps them compare the potential benefits and harms of a new medicine with other medicines.

References

1. Pharmaceutical Benefits Advisory Committee. Positive Recommendations made by the PBAC — July 2009. Canberra: Australian Government Department of Health and Ageing, 2009. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbacrec-jul09-positive (accessed 23 Sept 2009).
2. National Institute for Health and Clinical Excellence. Parkinson's disease: diagnosis and management in primary and secondary care. NICE clinical guideline 35. 2006. http://www.nice.org.uk/Guidance/CG35 (accessed 4 Aug 2009).
3. Neurology Writing Group. Therapeutic Guidelines: Neurology. Version 3. Melbourne: Therapeutic Guidelines Ltd, 2007.
4. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 2000;284:1931–8. [PubMed]
5. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044–53. [PubMed]
6. Rossi S (ed). Australian Medicines Handbook 2009. Adelaide: Australian Medicines Handbook Pty Ltd, 2009.
7. Biglan KM, Holloway RG Jr, McDermott MP, et al. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 2007;69:187–95. [PubMed]
8. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338–47. [PubMed]
9. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. JAMA 1997;278:125–30. [PubMed]
10. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group.[Erratum appears in Neurology 1998 Mar;50(3):838]. Neurology 1997;49:724–8. [PubMed]
11. Plant R, Walton G, Ashburn A, et al. Guidelines for physiotherapy practice in Parkinson's disease. Newcastle, UK: University of Northumbria, Institute of Rehabilitation: 2001. http://hces.unn.ac.uk/guidelines (accessed 4 Aug 2009).
12. Boehringer Ingelheim Pty Limited. Australia. Sifrol product information. 15 December 2008.
13. Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ 2002;324:1483–7. [PubMed]
14. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29–38. [PubMed]
15. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39–46. [PubMed]
16. Baxter K, ed. Stockley's Drug Interactions. 8^th edn. London: Pharmaceutical Press, 2008.